Signal2026-04-21
ClinicalTrials.gov

[PHASE2] A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency

Part of

Emerging Biomolecular Targets In Therapy

Open primary sourceSee the whole picture